Table 1.
Patients’ characteristics according to cytogenetic risk groups
| Cytogenetic risk groups | Low (n = 64) | Intermediate (n = 19) | High (n = 30) | Statistics (p) |
|---|---|---|---|---|
| Age at diagnosis, mean (±SD) | 64.4 (± 9.4) | 67.8 (± 8.2) | 64.9 (± 10.7) | NS |
| Age at study entry, mean (±SD) | 68.7 (± 9.3) | 72.2 (± 8.4) | 69.7 (± 9.8) | NS |
| Binet stage, No. of patients (%) | 0.05 | |||
| A | 50/64 (78.1%) | 11/19 (57.9%) | 16/30 (51.7%) | |
| B | 8/64 (12.5%) | 5/19 (26.3%) | 11/30 (37.9%) | |
| C | 6/64 (9.4%) | 3/19 (15.8%) | 3/30 (10.3%) | |
| Lymphocytosis (Giga/L), mean (±SD) | 30.7 (± 29.3) | 74.7 (± 71.1) | 49.6 (± 40.60) | 0.006 |
| IGHV mutational status, No. of patients (%) | NS | |||
| Unmutated (≥ 98% homology) | 1/22 (4.5%) | 2/12 (16.7%) | 3/10 (30%) | |
| Mutated (< 98% homology) | 21/22 (95.5%) | 10/12 (83.3%) | 7/10 (70%) | |
| CD38 > 30%, No. of patients (%) | 12/58 (20.7%) | 9/19 (47.4%) | 6/25 (24%) | NS |
| LDT from diagnosis, median (months)a | 48 | 24 | 17 | 0.0004 |
| PFS, median (months)a | > 120 | 72 | 40 | 0.003 |
| TFS, median (months)a | > 120 | 77 | 72 | 0.001 |
Abbreviations: NS not significant, No. number, SD standard deviation, IGHV immunoglobulin heavy-chain variable region, LDT lymphocyte doubling time, PFS progression-free survival, TFS treatment-free survival
aKaplan–Meier survival analysis